NovaBay Pharmaceuticals, Inc.
NBY
$0.58
-$0.02-3.33%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -1.21M | -1.59M | -3.21M | -4.11M | -1.76M |
| Total Depreciation and Amortization | 95.00K | 179.00K | 12.00K | 50.00K | 95.00K |
| Total Amortization of Deferred Charges | 145.00K | 311.00K | 415.00K | 571.00K | 662.00K |
| Total Other Non-Cash Items | 22.00K | 287.00K | 952.00K | 2.64M | 748.00K |
| Change in Net Operating Assets | -1.11M | 230.00K | 57.00K | 537.00K | -112.00K |
| Cash from Operations | -2.06M | -578.00K | -1.78M | -314.00K | -364.00K |
| Capital Expenditure | -2.00K | -2.00K | -2.00K | -2.00K | -1.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 0.00 | 0.00 | 1.07M | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -2.00K | -2.00K | 1.07M | -2.00K | -1.00K |
| Total Debt Issued | -- | -- | -- | 0.00 | 0.00 |
| Total Debt Repaid | -790.00K | -622.00K | -578.00K | -704.00K | -577.00K |
| Issuance of Common Stock | 2.88M | 226.00K | -- | 565.00K | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -96.00K | -19.00K | 113.00K | 0.00 |
| Cash from Financing | 2.09M | -492.00K | -597.00K | -26.00K | -577.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -277.00K |
| Net Change in Cash | 26.00K | -1.07M | -1.31M | -342.00K | -1.22M |
